Compare Abbott India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUN PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUN PHARMA ABBOTT INDIA/
SUN PHARMA
 
P/E (TTM) x 51.4 461.1 11.2% View Chart
P/BV x 16.8 2.8 590.6% View Chart
Dividend Yield % 0.4 0.6 72.9%  

Financials

 ABBOTT INDIA   SUN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
SUN PHARMA
Mar-19
ABBOTT INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs8,834679 1,301.4%   
Low Rs5,458375 1,453.8%   
Sales per share (Unadj.) Rs1,731.1121.1 1,429.0%  
Earnings per share (Unadj.) Rs211.913.4 1,584.3%  
Cash flow per share (Unadj.) Rs219.920.7 1,063.1%  
Dividends per share (Unadj.) Rs65.002.75 2,363.6%  
Dividend yield (eoy) %0.90.5 174.4%  
Book value per share (Unadj.) Rs945.2172.6 547.7%  
Shares outstanding (eoy) m21.252,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.14.4 94.9%   
Avg P/E ratio x33.739.4 85.6%  
P/CF ratio (eoy) x32.525.5 127.5%  
Price / Book Value ratio x7.63.1 247.5%  
Dividend payout %30.720.6 149.2%   
Avg Mkt Cap Rs m151,8481,264,650 12.0%   
No. of employees `0003.517.5 19.9%   
Total wages/salary Rs m4,35659,671 7.3%   
Avg. sales/employee Rs Th10,555.516,608.1 63.6%   
Avg. wages/employee Rs Th1,249.93,409.6 36.7%   
Avg. net profit/employee Rs Th1,292.21,833.8 70.5%   
INCOME DATA
Net Sales Rs m36,786290,659 12.7%  
Other income Rs m1,13310,255 11.0%   
Total revenues Rs m37,919300,914 12.6%   
Gross profit Rs m6,04763,076 9.6%  
Depreciation Rs m16917,533 1.0%   
Interest Rs m235,553 0.4%   
Profit before tax Rs m6,98950,246 13.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m2,4856,009 41.4%   
Profit after tax Rs m4,50332,093 14.0%  
Gross profit margin %16.421.7 75.8%  
Effective tax rate %35.612.0 297.4%   
Net profit margin %12.211.0 110.9%  
BALANCE SHEET DATA
Current assets Rs m27,610310,692 8.9%   
Current liabilities Rs m8,569173,396 4.9%   
Net working cap to sales %51.847.2 109.6%  
Current ratio x3.21.8 179.8%  
Inventory Days Days6099 60.8%  
Debtors Days Days27112 24.6%  
Net fixed assets Rs m1,057232,477 0.5%   
Share capital Rs m2132,399 8.9%   
"Free" reserves Rs m19,873411,691 4.8%   
Net worth Rs m20,086414,091 4.9%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m29,409646,938 4.5%  
Interest coverage x311.610.0 3,100.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.4 278.4%   
Return on assets %15.45.8 264.5%  
Return on equity %22.47.8 289.3%  
Return on capital %34.910.2 343.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36966,025 0.6%   
Fx outflow Rs m4,91838,610 12.7%   
Net fx Rs m-4,54927,415 -16.6%   
CASH FLOW
From Operations Rs m4,99121,965 22.7%  
From Investments Rs m-2,570-6,813 37.7%  
From Financial Activity Rs m-1,428-27,305 5.2%  
Net Cashflow Rs m993-8,442 -11.8%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.1 154.0%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.3 206.0%  
Shareholders   18,270 133,026 13.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PIRAMAL ENTERPRISES  GSK PHARMA  FRESENIUS KABI ONCO.  DR. REDDYS LAB  NOVARTIS  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Equitas Small Finance Bank IPO, LIC Q2 Stake Hike in Companies, and Top Buzzing Stocks Today(Pre-Open)

It was indeed a volatile trading day for share markets in India yesterday. After staging a gap-up opening, Indian share markets reversed gains.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 21, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - STERLING BIOTECH COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS